Promega Madison Achieves ISO 14001 Certification for Environmental Management
Promega Corporation announced today that its headquarters in Madison, Wisconsin has achieved ISO 14001:2015 certification, an internationally recognized standard for environmental management systems. This certification reflects the biotechnology manufacturer’s longstanding commitment to environmental stewardship and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505641030/en/
Promega Madison has achieved ISO 14001:2015 certification for its environmental management system. Promega announced the certification in its annual Corporate Responsibility Report, which also features sustainability metrics and details on how the biotechnology manufacturer supports scientists, employees and communities.
“For more than 45 years, Promega has been dedicated to environmental management and sustainable practices within the life sciences industry,” says Jaime Dwight, Director, Environmental Health & Safety and Controlled Substances. “This certification embodies the effort we have invested in fostering a culture of environmental responsibility, ensuring environmental compliance and promoting continual improvement across our operations.”
Promega announced the certification in its 2025 Corporate Responsibility Report, published today on the company’s website. In addition to sustainability metrics, the report captures how Promega supports scientists, employees and communities.
ISO 14001:2015 Certification
ISO 14001:2015 is an internationally recognized standard for environmental management systems. It provides a framework for organizations to identify, manage, monitor and improve their environmental performance. The standard helps businesses reduce waste, comply with regulations and minimize their environmental impact while enhancing sustainability efforts.
To achieve this certification, Promega demonstrated a strong environmental management system including adherence to environmental compliance requirements, mitigating environmental impact of our operations, and leadership commitment to sustainable best practices. A thorough review by independent auditors confirmed the company’s efforts in these areas.
Examples of Promega environmental initiatives include:
- Innovative product design that incorporates green chemistry and ambient shipping stability
- A global commitment to sourcing 100% renewable electricity by the end of 2025
- Employee-driven programs such as plastic film collection and recycling
- On-site composting to support the company garden using food and landscaping waste
2025 Corporate Responsibility Report
Since 2008, Promega has issued an annual Corporate Responsibility Report detailing its progress in sustainability, product impact, employee well-being and community engagement. Highlights of this year’s report include:
- Supporting Young Scientists: The Promega Rising Researchers Scientific Innovation Awards honor exceptional PhD students around the world with resources, mentorship and a visit to Promega Madison.
- Giving Back to Communities: The Promega in Action initiative gives Madison-based employees the opportunity to receive up to 40 hours of paid time off to volunteer for a nonprofit organization of their choice.
- Investing in Research and Innovation: Promega invested 13.8% of its revenue in R&D in 2024, propelling advancements in drug discovery, bioluminescence imaging and cellular metabolism.
The 2025 Corporate Responsibility Report contains additional information on how Promega considers the United Nations Sustainable Development Goals (SDGs) in its practices and actions.
Read the latest Corporate Responsibility Report here.
About Promega Corporation
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and veterinary, agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. Learn more at promega.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250505641030/en/
Contacts
Penny Patterson
VP, Corporate Affairs
Promega Corporation
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release
Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release
Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor
Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release
Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom